The pressure points across mass torts continue to shift, and this week’s Tort Talk highlights major moves in Roundup, J&J Talc, Tylenol, and the emerging AI-related suicide litigation.
Roundup: Bayer has withdrawn appeals on several major plaintiff verdicts, including the headline $2.1B Georgia case. Similar moves in Philadelphia suggest a broader strategy to resolve appeals while awaiting a potential Supreme Court ruling on preemption.
Talc: The first post-bankruptcy ovarian cancer trial against Johnson & Johnson is underway in California. Early testimony from the former FDA commissioner has intensified pressure ahead of additional trials set for 2026.
Tylenol: The Second Circuit heard arguments on whether the MDL judge improperly excluded all plaintiff experts. The panel’s questioning indicates the court may reconsider the standard applied, a decision that could revive one of the largest potential mass torts in years.
ChatGPT Suicide Litigation: Several new cases allege individuals interacted with ChatGPT before harming themselves, raising urgent questions about AI safety and the need for clearer guardrails.
Joe Fantini breaks down why these developments matter and how they shape the strategy heading into 2026.
————————— Contents of this video —————————
00:00 – Intro: Tort Talks with Jon Robinson, Marc Rioux, and Joe Fantini
00:23 – Roundup: Bayer Withdraws Appeals and Signals Settlement Strategy
01:46 – Talc: First Post-Bankruptcy Trial Opens in California
02:59 – Tylenol: Second Circuit Oral Argument Signals Possible Shift
05:08 – ChatGPT Suicide Cases: Emerging AI-Related Litigation
06:43 – Closing: Thanksgiving Hiatus and December Power Rankings Preview